Ulka Vaishampayan, MD, is a Professor of Internal Medicine, Leader of the Translational and Clinical Research Program and the Director of the Phase 1 Program at the University of Michigan and Rogel Cancer Center. She serves as the Chair of the SWOG Advanced Renal Committee, a member of the National Cancer Institute (NCI) Renal Task Force, and a board member of the Michigan Society of Hematology/Oncology. She organizes annual educational meetings for MSHO and has chaired OncLive meetings. Dr. Vaishampayan specializes in the treatment of genitourinary malignancies, and her research focuses on translational drug development. She is PI of the Dept of Defense Kidney Cancer Consortium site and is a co-PI recipient of the Prostate cancer Foundation Challenge Award. She has completed leadership training and has acquired the prestigious Fellowship of the Advisory Board (FAB). She has co-chaired the first SWOG DEI symposium in Apr 2022.  She has served as chair of the GU non prostate track of the Education Committee of the American Society of Clinical Oncology.   She has published in a number of peer reviewed journals such as Journal of Clinical Oncology, Clinical Cancer Research, Cancer, and Urology and has been a coauthor on a paper in the prestigious New England J Medicine.  She has also authored numerous review articles, editorials and book chapters.  She is an active reviewer for a number of journals including Lancet, Annals of Oncology, JAMA Oncology, J Clin Oncol, Clin Cancer res, and Int J of Rad Oncol, Biol and Physics. Dr. Vaishampayan has conducted clinical research in the management of GU cancers and clinical trials with a variety of novel agents in early therapeutics and translational settings.  Her research interests also include trying to evaluate novel pathways and biomarkers in cancers.